|
covid-19 |
133 |
|
humans |
91 |
|
sars-cov-2 |
82 |
|
mortality |
76 |
|
epidemiology |
70 |
|
adult |
67 |
|
male |
65 |
|
animals |
63 |
|
chinese |
62 |
|
diabetes |
58 |
|
female |
54 |
|
children |
53 |
|
inflammation |
53 |
|
apoptosis |
52 |
|
cardiovascular disease |
50 |
|
obesity |
47 |
|
aged |
44 |
|
cancer |
44 |
|
interprofessional education |
44 |
|
diabetes mellitus |
43 |
|
middle aged |
43 |
|
stroke |
41 |
|
hong kong |
40 |
|
public health |
40 |
|
atrial fibrillation |
39 |
|
covid-19 vaccine |
39 |
|
mice |
38 |
|
oxidative stress |
38 |
|
cardiovascular diseases |
37 |
|
dementia |
37 |
|
depression |
37 |
|
hypertension |
37 |
|
medical sciences |
37 |
|
heart failure |
36 |
|
osteoporosis |
36 |
|
adiponectin |
34 |
|
pharmacoepidemiology |
32 |
|
rats |
31 |
|
china |
30 |
|
cohort studies |
30 |
|
cohort study |
30 |
|
nitric oxide |
30 |
|
bnt162b2 |
29 |
|
breast cancer |
29 |
|
coronavac |
29 |
|
myocardial infarction |
29 |
|
vaccine safety |
29 |
|
atherosclerosis |
28 |
|
partnership model |
28 |
|
reactive oxygen species |
28 |
|
social interaction anxiety |
28 |
|
type 2 diabetes |
28 |
|
type 2 diabetes mellitus |
28 |
|
amino acid sequence |
27 |
|
cells, cultured |
27 |
|
covid-19 vaccines |
27 |
|
innate immunity |
27 |
|
meta-analysis |
27 |
|
chronic kidney disease |
26 |
|
cytokines |
26 |
|
insulin resistance |
26 |
|
cell line |
25 |
|
colorectal cancer |
25 |
|
molecular sequence data |
25 |
|
hepatocellular carcinoma |
24 |
|
machine learning |
24 |
|
safety |
24 |
|
asthma |
23 |
|
risk factors |
23 |
|
alzheimer's disease |
22 |
|
biomarker |
22 |
|
blood pressure |
22 |
|
dose-response relationship, drug |
22 |
|
ischemic stroke |
22 |
|
infants |
21 |
|
pregnancy |
21 |
|
prevalence |
21 |
|
reactive oxygen species - metabolism |
21 |
|
sars-cov-2 infection |
21 |
|
school closure |
21 |
|
blotting, western |
20 |
|
fracture |
20 |
|
lung cancer |
20 |
|
metformin |
20 |
|
multimorbidity |
20 |
|
vitamin d |
20 |
|
adolescent |
19 |
|
angiogenesis |
19 |
|
aspirin |
19 |
|
cholesterol |
19 |
|
endothelium |
19 |
|
sars |
19 |
|
secondary prevention |
19 |
|
vaccine effectiveness |
19 |
|
biology |
18 |
|
bone mineral density |
18 |
|
gut microbiota |
18 |
|
inactivated vaccine |
18 |
|
incidence |
18 |
|
macrophages |
18 |
|
primary care |
18 |
|
reverse transcriptase polymerase chain reaction |
18 |
|
rna, messenger - metabolism |
18 |
|
self-controlled case series |
18 |
|
signal transduction - drug effects |
18 |
|
traditional chinese medicine |
18 |
|
tuberculosis |
18 |
|
adipose tissue |
17 |
|
adolescents |
17 |
|
aging |
17 |
|
coronavirus |
17 |
|
health outcomes |
17 |
|
health sciences |
17 |
|
insulin |
17 |
|
long covid |
17 |
|
mendelian randomization |
17 |
|
systematic review |
17 |
|
adult learning principles |
16 |
|
autophagy |
16 |
|
body mass index |
16 |
|
bronchiectasis |
16 |
|
cell line, tumor |
16 |
|
child psychosocial problems |
16 |
|
collaborative practice |
16 |
|
cyclooxygenase |
16 |
|
effectiveness |
16 |
|
endothelial cells |
16 |
|
evaluation |
16 |
|
gene expression |
16 |
|
genotype |
16 |
|
healthcare workers |
16 |
|
home confinement |
16 |
|
hospital policies |
16 |
|
immunohistochemistry |
16 |
|
metabolic syndrome |
16 |
|
perceived stress |
16 |
|
pharmacy and pharmacology environmental studies |
16 |
|
polymorphism, single nucleotide |
16 |
|
psychological wellbeing |
16 |
|
time factors |
16 |
|
toxicology and environmental safety |
16 |
|
warfarin |
16 |
|
adverse events |
15 |
|
amino acid substitution |
15 |
|
ampk |
15 |
|
apoptosis - drug effects |
15 |
|
base sequence |
15 |
|
biomarkers |
15 |
|
chinese medicine |
15 |
|
ckd |
15 |
|
colon cancer |
15 |
|
ehr |
15 |
|
endothelial function |
15 |
|
hypercholesterolemia |
15 |
|
nf-κb |
15 |
|
odds ratio |
15 |
|
rats, sprague-dawley |
15 |
|
signal transduction |
15 |
|
tissue distribution |
15 |
|
aged, 80 and over |
14 |
|
algorithms |
14 |
|
antioxidants |
14 |
|
bacteria |
14 |
|
calcium |
14 |
|
cell proliferation - drug effects |
14 |
|
complications |
14 |
|
coronavirus infection |
14 |
|
electronic health records |
14 |
|
immunoglobulin |
14 |
|
kinetics |
14 |
|
metabolism |
14 |
|
mice, inbred c57bl |
14 |
|
protein structure, tertiary |
14 |
|
proteomics |
14 |
|
rheumatoid arthritis |
14 |
|
screen time |
14 |
|
sex difference |
14 |
|
statins |
14 |
|
validation |
14 |
|
all-cause mortality |
13 |
|
asian continental ancestry group |
13 |
|
bone density |
13 |
|
chemicals and cas registry numbers |
13 |
|
cigarette smoking |
13 |
|
diabetic cardiomyopathy |
13 |
|
efficacy |
13 |
|
lipocalin-2 |
13 |
|
lymphocyte subsets |
13 |
|
major adverse cardiovascular events |
13 |
|
menopause |
13 |
|
molnupiravir |
13 |
|
nirmatrelvir-ritonavir |
13 |
|
osteoporotic fractures |
13 |
|
paediatrics |
13 |
|
polymerase chain reaction |
13 |
|
pulmonary delivery |
13 |
|
rna interference |
13 |
|
up-regulation |
13 |
|
adipokine |
12 |
|
allergy |
12 |
|
animal experiment |
12 |
|
antibiotics |
12 |
|
anticoagulant |
12 |
|
antiresorptives |
12 |
|
asia |
12 |
|
blotting, northern |
12 |
|
chronic diseases |
12 |
|
chronic liver disease |
12 |
|
cigarette smoke |
12 |
|
cirrhosis |
12 |
|
convalescence |
12 |
|
electrophoresis, gel, two-dimensional |
12 |
|
endothelial dysfunction |
12 |
|
enzyme inhibitors - pharmacology |
12 |
|
enzyme-linked immunosorbent assay |
12 |
|
false positive |
12 |
|
gene frequency |
12 |
|
health economics |
12 |
|
health services |
12 |
|
hip fractures |
12 |
|
hong kong - epidemiology |
12 |
|
hyperthyroidism |
12 |
|
hypothyroidism |
12 |
|
hypoxia |
12 |
|
kawasaki disease |
12 |
|
liver injury |
12 |
|
mitochondria |
12 |
|
models, biological |
12 |
|
mrna vaccine |
12 |
|
myocarditis |
12 |
|
non-communicable diseases |
12 |
|
obstructive sleep apnea |
12 |
|
pericarditis |
12 |
|
plasma |
12 |
|
proliferation |
12 |
|
prospective studies |
12 |
|
sars-cov-2 rbd igg |
12 |
|
serology |
12 |
|
stress |
12 |
|
t cell response |
12 |
|
asian continental ancestry group - genetics |
11 |
|
bmd |
11 |
|
chronic disease |
11 |
|
clinical vertebral fractures |
11 |
|
cost-effectiveness |
11 |
|
disease models, animal |
11 |
|
double-blind method |
11 |
|
graves disease |
11 |
|
hypersensitivity |
11 |
|
lipid |
11 |
|
lipids |
11 |
|
nanoparticles |
11 |
|
older adults |
11 |
|
older people |
11 |
|
omicron |
11 |
|
pasc |
11 |
|
pharmacovigilance |
11 |
|
pharmacy |
11 |
|
pneumonia |
11 |
|
post-covid-19 syndrome |
11 |
|
prostaglandin e2 |
11 |
|
respiratory diseases |
11 |
|
sglt2 inhibitor |
11 |
|
statistics & research methods |
11 |
|
therapeutics |
11 |
|
thyroid dysfunction |
11 |
|
thyroid function tests |
11 |
|
thyroid gland |
11 |
|
thyroiditis |
11 |
|
time in therapeutic range |
11 |
|
upper limb fractures |
11 |
|
vaccination |
11 |
|
vaccine |
11 |
|
5-fluorouracil |
10 |
|
adipocytes - metabolism |
10 |
|
adipogenesis |
10 |
|
adolescence |
10 |
|
all-cause pneumonia |
10 |
|
antidepressants |
10 |
|
antioxidants - pharmacology |
10 |
|
antiplatelet |
10 |
|
anxiety |
10 |
|
asparaginase |
10 |
|
attention-deficit/hyperactivity disorder |
10 |
|
autoimmune disorders |
10 |
|
beta-amyloid |
10 |
|
binding sites |
10 |
|
biological sciences |
10 |
|
bone density - genetics |
10 |
|
case-control studies |
10 |
|
catalase |
10 |
|
causality |
10 |
|
comorbidity |
10 |
|
contraction |
10 |
|
cytokine |
10 |
|
delirium |
10 |
|
disease progression |
10 |
|
drug delivery |
10 |
|
electronic health record |
10 |
|
electronic medical records |
10 |
|
endothelium-derived contracting factor |
10 |
|
enos |
10 |
|
enzyme activation - drug effects |
10 |
|
gastrointestinal haemorrhage |
10 |
|
gene expression regulation |
10 |
|
health equity |
10 |
|
herbal medicine |
10 |
|
herd immunity |
10 |
|
human leukocyte antigens |
10 |
|
incident cvd |
10 |
|
inflammatory bowel disease |
10 |
|
interleukin-6 |
10 |
|
interrupted time series |
10 |
|
interrupted time series analysis |
10 |
|
linkage disequilibrium |
10 |
|
lithium |
10 |
|
macrophage |
10 |
|
mass spectrometry |
10 |
|
mitochondrial dysfunction |
10 |
|
osteoarthritis |
10 |
|
oxidation-reduction |
10 |
|
oxidative stress - drug effects |
10 |
|
pediatrics |
10 |
|
phospholipids |
10 |
|
phosphorylation - drug effects |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population-based electronic health records |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
post-covid cvd |
10 |
|
prescribing |
10 |
|
proteomics - methods |
10 |
|
proton pump inhibitors |
10 |
|
real-world evidence |
10 |
|
risk factor |
10 |
|
saponin |
10 |
|
sequence alignment |
10 |
|
sirt1 |
10 |
|
telomere |
10 |
|
treatment outcome |
10 |
|
2-de |
9 |
|
a-fabp |
9 |
|
abdominal pain |
9 |
|
adipokines |
9 |
|
advanced glycation end-products |
9 |
|
adverse events of special interest (aesi) |
9 |
|
age-stratified |
9 |
|
animal cell |
9 |
|
antimicrobials |
9 |
|
association |
9 |
|
barriers |
9 |
|
biological markers - blood |
9 |
|
body weight |
9 |
|
bone loss |
9 |
|
bradykinin |
9 |
|
cardiovascular complications |
9 |
|
cell membrane - metabolism |
9 |
|
chronic obstructive pulmonary disease |
9 |
|
cloning, molecular |
9 |
|
covid |
9 |
|
dna-binding proteins - genetics - metabolism |
9 |
|
down syndrome |
9 |
|
drug utilization |
9 |
|
extraction |
9 |
|
follow-up studies |
9 |
|
genetic association |
9 |
|
genetics |
9 |
|
genome-wide association study |
9 |
|
glycosylation |
9 |
|
green tea |
9 |
|
heart |
9 |
|
hela cells |
9 |
|
in situ hybridization |
9 |
|
infection |
9 |
|
intermittent hypoxia |
9 |
|
lean mass |
9 |
|
lipid metabolism |
9 |
|
lipoproteins |
9 |
|
liver |
9 |
|
liver - metabolism |
9 |
|
medicine |
9 |
|
mice, knockout |
9 |
|
microvascular complications |
9 |
|
mutation |
9 |
|
nursing |
9 |
|
organic acid |
9 |
|
parkinson's disease |
9 |
|
physical activity |
9 |
|
polymorphism, genetic |
9 |
|
polysaccharides |
9 |
|
primary health care |
9 |
|
protein binding |
9 |
|
proteins - genetics |
9 |
|
regression analysis |
9 |
|
relaxation |
9 |
|
rna, messenger - analysis |
9 |
|
serotonin |
9 |
|
serum 25-hydroxyvitamin d |
9 |
|
spermatogenesis - physiology |
9 |
|
spray drying |
9 |
|
superoxide dismutase |
9 |
|
transfection |
9 |
|
travel history |
9 |
|
trends |
9 |
|
undergraduate students |
9 |
|
vascular smooth muscle |
9 |
|
viral disease |
9 |
|
waning vaccine effectiveness |
9 |
|
wound healing |
9 |
|
adhd |
8 |
|
adherence |
8 |
|
adipocyte |
8 |
|
adiponectin receptor |
8 |
|
adverse events of special interest |
8 |
|
age-specific association |
8 |
|
anoxia - metabolism |
8 |
|
anti-inflammatory agents - pharmacology |
8 |
|
antimicrobial resistance |
8 |
|
antineoplastic activity |
8 |
|
antivirals |
8 |
|
anxiety disorder |
8 |
|
aorta |
8 |
|
apoptosis - drug effects - physiology |
8 |
|
appswe/ps1de9 |
8 |
|
aquaporin 9 |
8 |
|
aβ |
8 |
|
bacteremia |
8 |
|
blood-brain barrier |
8 |
|
bnt162b2 mrna covid-19 vaccines |
8 |
|
cdars |
8 |
|
chemotherapy |
8 |
|
child |
8 |
|
chinese population |
8 |
|
clinical pharmacology |
8 |
|
coffee |
8 |
|
cognitive impairments |
8 |
|
copd |
8 |
|
coronary artery disease |
8 |
|
covid-19 pandemic |
8 |
|
cytotoxicity |
8 |
|
dabigatran |
8 |
|
diarrhoea |
8 |
|
dimerization |
8 |
|
drug regulatory |
8 |
|
emulated trial |
8 |
|
endothelium-dependent contractions |
8 |
|
endothelium-derived contracting factors |
8 |
|
endotoxemia |
8 |
|
epithelial cells |
8 |
|
escherichia coli |
8 |
|
family hardship |
8 |
|
fib-4 |
8 |
|
free radicals |
8 |
|
gastroenterology |
8 |
|
general practice |
8 |
|
genetic predisposition to disease |
8 |
|
geriatrics |
8 |
|
glycolipids |
8 |
|
health disparity |
8 |
|
hemoglobin a1c |
8 |
|
hepatocytes - metabolism |
8 |
|
herbal medicines |
8 |
|
high-fat diet |
8 |
|
histamine |
8 |
|
hospitalisation |
8 |
|
hydrogen peroxide |
8 |
|
hypercytokinemia |
8 |
|
hyperglycemia |
8 |
|
hypertriglyceridemia |
8 |
|
immunosuppression |
8 |
|
indirect effect |
8 |
|
influenza |
8 |
|
inhalation |
8 |
|
jak2/stat3 |
8 |
|
kir genetics |
8 |
|
latent class analysis |
8 |
|
liver fibrosis |
8 |
|
low-density lipoprotein cholesterol |
8 |
|
meningitis |
8 |
|
mental health |
8 |
|
metabolomic |
8 |
|
metalloporphyrins - pharmacology |
8 |
|
multiple organ complications |
8 |
|
mutagenesis, site-directed |
8 |
|
myocardial ischemia injury |
8 |
|
neonates |
8 |
|
nested case-control study |
8 |
|
neuroinflammation |
8 |
|
nfs |
8 |
|
nitric oxide - metabolism |
8 |
|
nk cells |
8 |
|
observational study |
8 |
|
offspring |
8 |
|
orphan drug policy |
8 |
|
p53 |
8 |
|
paediatric gastroenterology |
8 |
|
patch-clamp techniques |
8 |
|
pediatric population |
8 |
|
pedigree |
8 |
|
pharmacokinetics |
8 |
|
pharmacology |
8 |
|
pi3k/akt |
8 |
|
polysaccharide |
8 |
|
population-based |
8 |
|
preschooler |
8 |
|
primary care clinic |
8 |
|
primary prevention |
8 |
|
prognosis |
8 |
|
proto-oncogene proteins c-akt - metabolism |
8 |
|
rare diseases |
8 |
|
recurrent cardiovascular events |
8 |
|
risk prediction score |
8 |
|
self-harm |
8 |
|
severity |
8 |
|
smoking |
8 |
|
specialist outpatient clinics |
8 |
|
sphingolipids |
8 |
|
testis - cytology - physiology |
8 |
|
thiazolidinediones - therapeutic use |
8 |
|
transcription, genetic |
8 |
|
translation to patients |
8 |
|
treatment access |
8 |
|
trs 2°p |
8 |
|
two-dimensional gel electrophoresis |
8 |
|
vaccine-related myocarditis |
8 |
|
vasoconstriction - drug effects |
8 |
|
vasodilation - drug effects - physiology |
8 |
|
vitamin d binding protein |
8 |
|
zebrafish |
8 |
|
3t3 cells |
7 |
|
3t3-l1 cells |
7 |
|
access to healthcare |
7 |
|
acetic acid |
7 |
|
acetylcholine |
7 |
|
acetylcholine - pharmacology |
7 |
|
acrosome - physiology |
7 |
|
adenocarcinoma |
7 |
|
adrenergic beta-antagonists - pharmacology |
7 |
|
adverse drug reactions |
7 |
|
airway epithelial cells |
7 |
|
alcoholism |
7 |
|
alzheimer disease |
7 |
|
angiotensinconverting enzyme inhibitors |
7 |
|
antimicrobial stewardship |
7 |
|
antioxidant |
7 |
|
antipsychotics |
7 |
|
antiviral medications |
7 |
|
asians |
7 |
|
attention deficit hyperactivity disorder |
7 |
|
autism spectrum disorder |
7 |
|
bile acids |
7 |
|
binding, competitive |
7 |
|
bioactive compounds |
7 |
|
bioinformatics |
7 |
|
bipolar disorder |
7 |
|
blood glucose - metabolism |
7 |
|
blood–brain barrier |
7 |
|
bmi |
7 |
|
bone metabolism |
7 |
|
c-reactive protein |
7 |
|
calcitonin gene-related peptide |
7 |
|
cancer-associated venous thrombosis (cat) |
7 |
|
carbapenemase-producing enterobacteriaceae |
7 |
|
carriage |
7 |
|
catalase - metabolism |
7 |
|
cattle |
7 |
|
cell fractionation |
7 |
|
cell proliferation |
7 |
|
cer1 |
7 |
|
chronic respiratory disease |
7 |
|
colonoscopy |
7 |
|
coriolus versicolor |
7 |
|
cross-sectional studies |
7 |
|
cyclooxygenase-2 |
7 |
|
dexamethasone - pharmacology |
7 |
|
diabetes complications |
7 |
|
dialysis patients |
7 |
|
differentiation |
7 |
|
direct oral anticoagulants (doacs) |
7 |
|
dpp4 inhibitor |
7 |
|
drug discovery |
7 |
|
drug interactions |
7 |
|
drug modulation |
7 |
|
dyslipidemia |
7 |
|
early childhood exposure |
7 |
|
early-life activities |
7 |
|
elderly |
7 |
|
elderly care |
7 |
|
endocrinology |
7 |
|
endothelial nitric oxide synthase |
7 |
|
endothelin-1 |
7 |
|
endothelium, vascular - drug effects - enzymology - physiology |
7 |
|
endothelium, vascular - drug effects - metabolism - physiology |
7 |
|
endothelium, vascular - drug effects - metabolism - physiopathology |
7 |
|
endothelium-derived hyperpolarizing factor |
7 |
|
exercise |
7 |
|
family financial pressure |
7 |
|
fat |
7 |
|
fatty acid-binding proteins - blood |
7 |
|
focus group |
7 |
|
forced expiratory volume - physiology |
7 |
|
gender |
7 |
|
gene expression - drug effects |
7 |
|
genetic correlation |
7 |
|
genetic vectors |
7 |
|
gluconeogenesis |
7 |
|
glycated haemoglobin |
7 |
|
glycolysis |
7 |
|
guinea pigs |
7 |
|
haplotypes |
7 |
|
healthcare system |
7 |
|
heat-shock proteins - metabolism |
7 |
|
homeostasis |
7 |
|
ht-29 cells |
7 |
|
hyperglycaemia |
7 |
|
hypoglycemic agents - therapeutic use |
7 |
|
in situ hybridization, fluorescence |
7 |
|
indirect impact |
7 |
|
inducible nitric oxide synthase |
7 |
|
ischaemic stroke |
7 |
|
jnk |
7 |
|
jnk/c-jun signalling |
7 |
|
kidney |
7 |
|
left ventricular hypertrophy |
7 |
|
leguminosae |
7 |
|
lipid-lowering agents |
7 |
|
lipocalin |
7 |
|
lipopolysaccharide |
7 |
|
liver cancer |
7 |
|
low-molecular-weight heparin (lmwh) |
7 |
|
lumbar disc degeneration |
7 |
|
macrophage polarization |
7 |
|
markov state-transition model |
7 |
|
medicine, chinese traditional |
7 |
|
mental disorders |
7 |
|
metabolomics |
7 |
|
mice, inbred strains |
7 |
|
mmp-9 |
7 |
|
multiple reaction monitoring |
7 |
|
neuroprotection |
7 |
|
nf-kappa b - metabolism |
7 |
|
nfκb |
7 |
|
nhanes |
7 |
|
oncology |
7 |
|
peritoneal dialysis |
7 |
|
phosphorylation |
7 |
|
photodynamic therapy |
7 |
|
phylogeny |
7 |
|
pleiotropy |
7 |
|
polygenic score |
7 |
|
polyphenols |
7 |
|
population aging |
7 |
|
population-based study |
7 |
|
post-complication mortality |
7 |
|
ppar gamma - agonists - metabolism |
7 |
|
preferences |
7 |
|
proanthocyanidins |
7 |
|
promoter regions, genetic |
7 |
|
promoter regions, genetic - genetics |
7 |
|
prostacyclin |
7 |
|
prostaglandin |
7 |
|
protein kinase c - metabolism |
7 |
|
proteins - genetics - metabolism |
7 |
|
proteome |
7 |
|
pseudomonas aeruginosa |
7 |
|
psychosocial development |
7 |
|
quality-adjusted life years (qalys) |
7 |
|
rat |
7 |
|
recombinant fusion proteins - metabolism |
7 |
|
recombinant proteins - metabolism |
7 |
|
renal replacement therapy |
7 |
|
resistance |
7 |
|
salvia miltiorrhiza |
7 |
|
sarcopenia |
7 |
|
school closures |
7 |
|
school-aged children |
7 |
|
sequence analysis, dna |
7 |
|
sleep |
7 |
|
small interfering rna |
7 |
|
soluble guanylyl cyclase |
7 |
|
spermatozoa - cytology - metabolism |
7 |
|
substrate specificity |
7 |
|
survival |
7 |
|
tandem mass spectrometry |
7 |
|
thiazolidinediones |
7 |
|
tumor‐shrinking decoction |
7 |
|
type 1 diabetes |
7 |
|
ultra‐pressure liquid chromatography coupled tandem mass spectrometry |
7 |
|
vasoconstriction |
7 |
|
vasodilatation |
7 |
|
vasodilation |
7 |
|
vasodilation - drug effects |
7 |
|
vasodilator agents - pharmacology |
7 |
|
visceral fat |
7 |
|
visit‐to‐visit variability |
7 |
|
vital capacity |
7 |
|
waist circumference |
7 |
|
warburg effect |
7 |
|
zinc fingers |
7 |
|
25(oh)d |
6 |
|
acyl coenzyme a - metabolism |
6 |
|
adaptor protein |
6 |
|
adaptor proteins, signal transducing - genetics - metabolism |
6 |
|
adiponectin - genetics |
6 |
|
adiponectin - metabolism |
6 |
|
adipose tissue - chemistry |
6 |
|
adiposity - physiology |
6 |
|
administration, inhalation |
6 |
|
adverse drug reaction |
6 |
|
age |
6 |
|
age factors |
6 |
|
allele |
6 |
|
anaphylaxis |
6 |
|
angiotensin ii |
6 |
|
angiotensin receptor blockers |
6 |
|
angiotensin-converting enzyme inhibitors |
6 |
|
anti-coagulant |
6 |
|
anti-inflammation |
6 |
|
antiepileptics |
6 |
|
antihypertensive drugs |
6 |
|
appl1 |
6 |
|
arginine methylation |
6 |
|
biogenesis |
6 |
|
biological markers - analysis |
6 |
|
biotin |
6 |
|
bisphosphonates |
6 |
|
bleeding |
6 |
|
blood glucose - analysis |
6 |
|
bmi status |
6 |
|
bone mineral testing |
6 |
|
bone turnover markers |
6 |
|
bronchial epithelial cells |
6 |
|
bronchiectasis - metabolism |
6 |
|
burden of disease |
6 |
|
c-reactive protein - analysis |
6 |
|
caffeine |
6 |
|
camp |
6 |
|
cancer metabolism |
6 |
|
cancer therapy |
6 |
|
cardiovascular event |
6 |
|
cardiovascular mortality |
6 |
|
carotid artery |
6 |
|
carotid intima-media thickness |
6 |
|
cell density |
6 |
|
challenge |
6 |
|
chemical constituent |
6 |
|
child, preschool |
6 |
|
cilia |
6 |
|
ciliary central microtubular orientation |
6 |
|
collagen |
6 |
|
controlled study |
6 |
|
covid-19 incidence |
6 |
|
cox regression |
6 |
|
curcumin |
6 |
|
cvd |
6 |
|
cyclic amp - metabolism |
6 |
|
cyp2c9 |
6 |
|
cytokines - genetics |
6 |
|
cytotoxic activity |
6 |
|
data repository |
6 |
|
depolarization |
6 |
|
diabetes mellitus, type 2 - blood - drug therapy |
6 |
|
dipeptidyl peptidase-4 inhibitors |
6 |
|
disease and disorders of/related to bone |
6 |
|
dna, complementary - genetics |
6 |
|
doac |
6 |
|
doxorubicin |
6 |
|
drug |
6 |
|
drug safety |
6 |
|
dry powder inhaler |
6 |
|
electrophysiology |
6 |
|
endothelial progenitor cells |
6 |
|
endothelial senescence |
6 |
|
endothelium, vascular - metabolism |
6 |
|
endothelium, vascular - physiology |
6 |
|
energy metabolism |
6 |
|
ep4 |
6 |
|
epidemiological studies |
6 |
|
erxian decoction |
6 |
|
erythrocytes - enzymology |
6 |
|
escherichia coli - genetics |
6 |
|
esophageal cancer |
6 |
|
estrogen receptor |
6 |
|
fatty liver |
6 |
|
fatty liver disease |
6 |
|
fgf21 |
6 |
|
fracture prevention |
6 |
|
fractures, bone - genetics |
6 |
|
ganoderma lucidum |
6 |
|
gastrointestinal bleeding |
6 |
|
gastrointestinal tumours |
6 |
|
gc gene |
6 |
|
gene |
6 |
|
gene expression profiling - methods |
6 |
|
general diabetes |
6 |
|
general population studies |
6 |
|
genetic disease |
6 |
|
genistein |
6 |
|
genome-wide haplotype association mapping (ham) |
6 |
|
genomics |
6 |
|
gleditsia sinensis |
6 |
|
glucocorticoid receptor |
6 |
|
glucocorticoids |
6 |
|
glucose intolerance - blood - genetics |
6 |
|
glutathione peroxidase |
6 |
|
glyburide - therapeutic use |
6 |
|
glycemic control |
6 |
|
hdl‐c |
6 |
|
health policy |
6 |
|
healthcare resource |
6 |
|
heme oxygenase-1 |
6 |
|
herb-drug interaction |
6 |
|
hormones |
6 |
|
human |
6 |
|
hydrogen-ion concentration |
6 |
|
hypertension - epidemiology |
6 |
|
hypertriglyceridemia - epidemiology |
6 |
|
igt |
6 |
|
immunotherapy |
6 |
|
impaired glucose tolerance |
6 |
|
infant, newborn |
6 |
|
intellectual disability |
6 |
|
intensive care unit |
6 |
|
interleukin-6 - biosynthesis |
6 |
|
interstitial lung disease |
6 |
|
intestinal mucositis |
6 |
|
intra-abdominal fat |
6 |
|
intracranial hemorrhage |
6 |
|
intubation |
6 |
|
isoproterenol |
6 |
|
japan |
6 |
|
ldl‐c |
6 |
|
leucine |
6 |
|
likelihood functions |
6 |
|
lipids variability |
6 |
|
lkb1 |
6 |
|
membrane proteins - biosynthesis |
6 |
|
messenger rna |
6 |
|
meta-data |
6 |
|
metabolic inflammation |
6 |
|
metabolic syndrome x - blood - epidemiology - etiology |
6 |
|
metastasis |
6 |
|
methylphenidate |
6 |
|
mice, obese |
6 |
|
microarray |
6 |
|
mineral metabolism |
6 |
|
motor performance |
6 |
|
multinational cohort study |
6 |
|
muscle contraction - drug effects |
6 |
|
muscle relaxation - drug effects |
6 |
|
muscle, smooth, vascular - drug effects - metabolism |
6 |
|
nafld |
6 |
|
nanotechnology |
6 |
|
neurogen |
6 |
|
neuroleptic agent |
6 |
|
neurological and mental health global epidemiology network |
6 |
|
non-alcoholic steatohepatitis |
6 |
|
non-st elevated myocardial infarction |
6 |
|
non-steroidal anti-inflammatory drugs |
6 |
|
norepinephrine - pharmacology |
6 |
|
nsaids |
6 |
|
obesity - epidemiology |
6 |
|
obesity - genetics |
6 |
|
oral anticoagulant |
6 |
|
organ culture techniques |
6 |
|
osteoblasts - metabolism |
6 |
|
osteoporosis - genetics - metabolism |
6 |
|
p-pkb |
6 |
|
paediatric |
6 |
|
pamam |
6 |
|
panax notoginseng |
6 |
|
personalized medicine |
6 |
|
ph domain and leucine zipper containing 1 (appl1) |
6 |
|
phosphotyrosine interaction |
6 |
|
phytotherapy |
6 |
|
pkm2 |
6 |
|
pneumonia admission |
6 |
|
pomegranate peel ellagitannins |
6 |
|
preschoolers |
6 |
|
preventive medicine |
6 |
|
prmt6 |
6 |
|
protein kinase c |
6 |
|
proteins - metabolism |
6 |
|
proto-oncogene proteins - genetics - metabolism |
6 |
|
psychological symptoms |
6 |
|
pulmonary hypertension |
6 |
|
quality control |
6 |
|
quality of life |
6 |
|
radioimmunoassay |
6 |
|
rage |
6 |
|
rats, inbred shr |
6 |
|
rats, inbred wky |
6 |
|
rats, wistar |
6 |
|
receptors, immunologic - blood - drug effects |
6 |
|
reference values |
6 |
|
renin |
6 |
|
respiratory tract infections |
6 |
|
retrospective cohort |
6 |
|
retrospective studies |
6 |
|
rhinitis |
6 |
|
rickets |
6 |
|
rna, messenger - biosynthesis |
6 |
|
rosiglitazone |
6 |
|
saponins - pharmacology |
6 |
|
self-assembly |
6 |
|
self-controlled case series study |
6 |
|
sensitivity and specificity |
6 |
|
sequence homology, amino acid |
6 |
|
single-nucleotide polymorphism |
6 |
|
sirt3 |
6 |
|
sleep apnea, obstructive - metabolism |
6 |
|
snoring |
6 |
|
sodium-glucose co-transporter |
6 |
|
sodium-glucose cotransporter-2 inhibitors |
6 |
|
soluble receptor for advanced glycation end-products |
6 |
|
southern chinese women |
6 |
|
spontaneously hypertensive rats |
6 |
|
st segment elevation myocardial infarction |
6 |
|
stability |
6 |
|
statin |
6 |
|
steroidogenic |
6 |
|
stomach |
6 |
|
stomach cancer |
6 |
|
structural identification |
6 |
|
structure-activity relationship |
6 |
|
suicide |
6 |
|
superoxide dismutase - metabolism |
6 |
|
supplementation |
6 |
|
swine |
6 |
|
telomere length |
6 |
|
thiazolidinedione |
6 |
|
timi grading system |
6 |
|
timosaponin aiii |
6 |
|
tnf receptor-associated factor 6 - genetics - metabolism |
6 |
|
toxicity |
6 |
|
tp receptors |
6 |
|
transcription factor gata 2 |
6 |
|
transmission electronic microscopy |
6 |
|
treatment |
6 |
|
tumor microenvironment |
6 |
|
tumor necrosis factor-α |
6 |
|
ubiquitination |
6 |
|
ulcerative colitis |
6 |
|
umbilical veins |
6 |
|
uncaria rhynchophylla |
6 |
|
variability |
6 |
|
vdr gene |
6 |
|
vitamin d-binding protein |
6 |
|
17β-estradiol |
5 |
|
5-hydroxytryptamine |
5 |
|
acetaminophen |
5 |
|
action potentials - drug effects |
5 |
|
adaptor proteins, signal transducing - antagonists and inhibitors - genetics - physiology |
5 |
|
adaptor proteins, signal transducing - metabolism |
5 |
|
adenine - analogs and derivatives - metabolism - pharmacology |
5 |
|
adenoviridae - genetics |
5 |
|
adipocyte fatty-acid-binding protein |
5 |
|
adiponectin - biosynthesis - metabolism |
5 |
|
adiponectin - blood - genetics - metabolism |
5 |
|
adiponectin - deficiency - therapeutic use |
5 |
|
adiponectin and adipokine |
5 |
|
adipose tissue - drug effects - metabolism |
5 |
|
adult cardiology |
5 |
|
adulthood |
5 |
|
adverse drug event |
5 |
|
aerosol |
5 |
|
affinity chromatography |
5 |
|
ageing |
5 |
|
aging - metabolism |
5 |
|
agranulocytosis |
5 |
|
alleles |
5 |
|
alzheimer’s disease |
5 |
|
amp-activated protein kinases - metabolism |
5 |
|
analgesia |
5 |
|
andrographolide derivative |
5 |
|
androstadienes - administration & dosage |
5 |
|
anesthesia |
5 |
|
anti-angiogenesis |
5 |
|
anti-inflammatory |
5 |
|
anticoagulation |
5 |
|
antidepressant |
5 |
|
antifungal |
5 |
|
antineoplastic agents - pharmacology |
5 |
|
antiplatelets |
5 |
|
aorta, thoracic - drug effects - metabolism - physiopathology |
5 |
|
appl2 |
5 |
|
asian population |
5 |
|
association study |
5 |
|
atenolol - pharmacology |
5 |
|
avascular necrosis |
5 |
|
bacteriuria |
5 |
|
bdmards |
5 |
|
berberine |
5 |
|
bioaccumulation |
5 |
|
biofilm |
5 |
|
biofilms |
5 |
|
biomedicine |
5 |
|
biostatistics |
5 |
|
blood glucose |
5 |
|
blood glucose - drug effects |
5 |
|
blood pressure - drug effects |
5 |